2024
Long-Term Use of Muscle Relaxant Medications for Chronic Pain
Oldfield B, Gleeson B, Morford K, Adams Z, Funaro M, Becker W, Merlin J. Long-Term Use of Muscle Relaxant Medications for Chronic Pain. JAMA Network Open 2024, 7: e2434835. PMID: 39298168, PMCID: PMC11413720, DOI: 10.1001/jamanetworkopen.2024.34835.Peer-Reviewed Original ResearchConceptsLow back painBack painSkeletal muscle relaxantsChronic painRandomized clinical trialsNeck painCohort studyEfficacy of long-term useLong-term useSystematically searched Ovid MEDLINEMuscle relaxant medicationsModerate risk of biasOpioid prescribing guidelinesRisk of biasQuality of cohort studiesWeb of SciencePainful crampsRelaxant medicationsChronic pain syndromesPainful spasmsOvid MEDLINEPrescribing guidelinesSystematic reviewIncreased prescriptionModerate risk
2022
The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study
Morford K, Tetrault J, Zhou B, Li F, Gleeson B, Edelman E, Stein M, Barry D, Madden L. The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study. Drug And Alcohol Dependence 2022, 241: 109707. PMID: 36423462, PMCID: PMC9777057, DOI: 10.1016/j.drugalcdep.2022.109707.Peer-Reviewed Original ResearchConceptsBenzodiazepine exposureRetrospective cohort studyKaplan-Meier analysisTreatment retentionCohort studyCox regressionTreatment durationMedian treatment durationMultivariable Cox regressionCohort of patientsOpioid treatment programsOpioid use disorderLog-rank testSame-day accessDrug Administration recommendationsTreatment discontinuationUrine toxicologyMeier analysisMethadone programsUse disordersPatientsAdministration recommendationsTreatment entryTreatment programTreatment barriers